MTII administered peripherally reduces fat without invoking apoptosis in rats

Area of Science:

• Endocrinology
• Neuroscience
• Metabolic Research

Background:

• The brain's melanocortin (MC) system is a key mediator of leptin signaling.
• Dysfunction in the MC system is linked to severe obesity.
• Melanotan II (MTII), an MC3/4-receptor agonist, mimics some leptin effects, including potential impacts on adipose tissue.

Purpose of the Study:

• To investigate whether MTII administration induces apoptosis in adipose tissue.
• To determine the effects of MTII on body weight, food intake, and fat mass in rats.
• To compare MTII's effects with leptin's known actions on fat depots.

Main Methods:

• Rats were administered MTII (2 mg/kg, i.p.) or saline daily for 4 days.
• A pair-fed (PF) group controlled for reduced food intake.
• Measurements included food/water intake, body weight, body temperature, adipose tissue mass, and serum free fatty acids.

Main Results:

• MTII significantly reduced food intake, water intake, body weight gain, and body temperature compared to controls.
• Retroperitoneal and epididymal white adipose tissue (WAT) mass decreased significantly after MTII treatment.
• While brown fat weight decreased in both MTII and PF groups, DNA fragmentation assays did not support MTII-induced apoptosis in fat tissues.

Conclusions:

• Intraperitoneal MTII administration reduces fat mass in rats, primarily through accelerated lipid mobilization rather than apoptosis.
• MTII effectively inhibits body weight gain and alters feeding behavior.
• The findings clarify the mechanism by which MTII impacts adipose tissue, distinguishing it from leptin's potential apoptotic effects.